Search

Cardiac muscle is myogenic and is capable of generating an action potential and depolarizing and repolarizing signals from within the muscle itself. An intrinsic conduction system (ICS), a group of specialized cardiac cells, passes an electrical signal throughout the heart. This technology is a method and associated system to identify a person based on the use of statistical parameters, peak amplitudes and/or time interval lengths and/or depolarization-repolarization vector angles and/or depolarization-repolarization vector lengths for PQRST electrical signals associated with heart waves. The statistical parameters, estimated to be at least 192, serve as biometric indicia to authenticate or to decline to authenticate an asserted identity of a candidate person. There are three on-line modes of operation enrollment, verification, and identification as well as two off-line modes statistics and settings. In enrollment the raw electrocardiography (ECG) signal is processed and the results in the form of parameters are serialized and saved. Verification and Identification procedures use the feature parameters for recognition (classification) of subjects based on the same kind of parameters (features) of heartbeats extracted from the ECG signal of a person to be verified or identified.

Many diseases are accompanied by characteristic odors. Their recognition can provide diagnostic clues, guide the laboratory evaluation, and affect the choice of immediate therapy. The study of the chemical composition of human breath using gas chromatography mass spectrometry (GC/MS) has shown a correlation between the volatile compounds and the occurrence of certain illnesses. The presence of those specific compounds can provide an indication of physiological malfunction and support the diagnosis of diseases. This condition requires an analytical tool with very high sensitivity for its measurement. A number of volatile compounds, so called biomarkers, are found in breath samples, normally at low parts per billion (ppb) levels. For example, the acetone in the exhaled breath from human with other biomarkers can indicate Type I diabetes. Usually, the concentration of the volatile compounds in human breath is very low and the background relative humidity is high, almost 100%. NASAs invention utilizes an array of chemical sensors combined with humidity, temperature, and pressure for real-time breath measurement to correlate the chemical information in the breath with the state and functioning of different human organs. This tool provides a non-invasive method for fast and accurate diagnosis at the medical point of care or at home. The sensor chip includes multisensors for a comprehensive measurement of chemical composition, temperature, humidity, and pressure/flow rate. The sensor data collected from this chip can be wired or wirelessly transmitted to a computer terminal at the doctors desk or hospital monitoring center. The sensor chip can be connected directly or via Universal serial bus (USB) to a cell phone for data transmission over a long distance and receive an instruction from a doctors office for an immediate therapy.

Once genes for a desired material type, delivery mode, control method and affinity have been chosen, assembling the genetic components and creating the cell lines can be done with well-established synthetic biology techniques. A 3D microdeposition system is used to make a 3D array of these cells in a precise, microstructure pattern and shape. The engineered cells are suspended in a printable 'ink'. The 3D microdeposition system deposits minute droplets of the cells onto a substrates surface in a designed print pattern. Additional printer passes thicken the material. The cell array is fed nutrients and reagents to activate the engineered genes within the cells to create and deposit the desired molecules. These molecules form the designed new material. If desired, the cells may be removed by flushing. The end product is thus a 3D composite microstructure comprising the novel material. This innovation provides a fast, controlled production of natural, synthetic, and novel biomaterials with minimum resource overhead and reduced pre- and post-processing requirements.

Gene expression analysis measures the activity of genes and reveals valuable information about the internal states of living cells. NASA Ames has developed a novel system for conducting quantitative, real-time gene expression analysis that not only significantly improves the sample preparation procedures and provides a quick, cost-effective solution needed in a laboratory, but also minimizes the risk of RNA contamination and degradation. The invention, a novel assay methodology and suite of devices have been developed to isolate nucleic acids from Prokaryotic and Eukaryotic cells and prepare samples for Reverse Transcriptase - quantitative Polymerase Chain Reaction (RT-qPCR) analysis. The invention consists of a method to extract and purify nucleic acids from biospecimen that does not require organics or toxic chemicals, and provides containment for the liquids. The assay employs an aqueous-based non-alcohol method that yields robust RNA quality; and PCR reaction tubes that are pre-loaded with stabilized lyophilized reagents designed to perform RT-qPCR analysis - all in all enabling rapid, cost effective, and portable manual operation in the laboratory or remote field environments. This innovative technology greatly reduces preparation time to less than 10% of the time it would take using standard techniques. This technology could be used with any commercial quantitative Polymerase Chain Reaction (qPCR) machine.

To assess various aspects of dynamic visual and visuomotor function including peripheral attention, spatial localization, perceptual motion processing, and oculomotor responsiveness, NASA developed a simple five-minute clinically relevant test that measures and computes more than a dozen largely independent eye-movement-based (oculometric) measures of human neural performance. This set of oculomotor metrics provide valid and reliable measures of dynamic visual performance and may prove to be a useful assessment tool for mild functional neural impairments across a wide range of etiologies and brain regions. The technology may be useful to clinicians to localize affected brain regions following trauma, degenerative disease, or aging, to characterize and quantify clinical deficits, to monitor recovery of function after injury, and to detect operationally-relevant altered or impaired visual performance at subclinical levels. This novel system can be used as a sensitive screening tool by comparing the oculometric measures of an individual to a normal baseline population, or from the same individual before and after exposure to a potentially harmful event (e.g., a boxing match, football game, combat tour, extended work schedule with sleep disruption, blast or toxic exposure, space mission), or on an ongoing basis to monitor performance for recovery to baseline. The technology provides set of largely independent metrics of visual and visuomotor function that are sensitive and reliable within and across observers, yielding a signature multidimensional impairment vector that can be used to characterize the nature of a mild deficit, not just simply detect it. Initial results from peer-reviewed studies of Traumatic Brain Injury, sleep deprivation with and without caffeine, and low-dose alcohol consumption have shown that this NASA technology can be used to assess subtle deficits in brain function before overt clinical symptoms become obvious, as well as the efficacy of countermeasures.

Microorganisms are unique from the standpoint that they can be employed as self-replicating bio-factories to produce both native and engineered mission relevant bio-products. Methane (CH4) usage in In-Space Manufacturing (ISM) platforms has been discussed previously for human exploration and has been proposed to be used in physicochemical systems as a propulsion fuel, supply gas, and in fuel cells. Carbon Dioxide (CO2) is abundant on Mars and manned spacecraft. On the International Space Station (ISS), NASA reacts excess CO2 with Hydrogen (H2) to generate CH4 and Water (H2O) using the Sabatier System (Figure 1). The resulting water is recovered in the ISS, but the methane is vented to space. Recapturing this methane and using it for microbial manufacturing could provide a unique approach in development of in-space bio-manufacturing. Thus, there is a capability need for systems that convert methane into valuable materials. Methane (CH4) is a potential carbon substrate for methanotrophic microorganisms which are able to metabolize CH4 into biomass. The innovative technology from NASA Ames Research Center ports Soluble Methane Monooxygenase (sMMO) to Pichia, that is, it moves the methane metabolism into a robust microbial factory (Pichia pastoris) (Figure 2). The yeast Pichia pastoris is a refined microbial factory that is used widely by industry because it efficiently secretes products. Pichia could produce a variety of useful products in space. Pichia does not consume methane but robustly consumes methanol, which is one enzymatic step removed from methane. This novel innovation engineers Pichia to consume methane thereby creating a powerful methane-consuming microbial factory and utilizing methane in a robust and flexible synthetic biology platform.

NASA’s electrochemical Enzyme-Linked Immunosorbent Assay (ELISA) microelectrode array biosensor advantageously incorporates a microbead detection construct, coupled with a magnetic immobilization construct, which substantially increases the signal sensitivity of a sensor. The magnetic immobilization construct draws the microbead detection construct to an electrode detection surface, enhancing signal sensitivity. By concentrating the signaling molecules close to the electrode detection surface, electrochemical redox cycling is achieved by reducing the distance between the two, allowing for regeneration of reporter molecules. Whereas a traditional ELISA testing exhibits five to ten signaling molecules per probe molecule binding event, the present electrochemical ELISA-based biosensor testing exhibits up to 4,857 signaling molecules per probe molecule binding event. The model bead construct exhibits a more than 6.75-fold in increased measured signal, and more than 35.7-fold improvement in signal sensitivity. When compared to traditional optical ELISA, the present invention improves the limit of detection by up to a factor of 60.5. NASA’s electromagnetic ELISA-based biosensor can be used for the detection of SARS-CoV-2 virus to enhance Covid-19 testing during the early phases of infection. The technology may also be modified to detect other biomarkers.

Expanded COBRA Oculometrics (ECO) expands the oculometric assessment into the peripheral visual field and sub-divides the visual field into sub-regions defined by their eccentricity (ring) and angular range (sector) for more direct comparison with current state-of-the-art clinical imagining (e.g., OCT (Optical Coherence Tomography)) and functional testing (e.g., perimetry) methodologies. ECO improves on COBRA in two ways, 1) ECO probes multiple rings at multiple eccentricities (nominally at ~3 and ~6 deg of eccentricity to correspond to classic OCT imaging measures) and 2) ECO subdivides the conventional COBRA analysis into angular sectors (nominally into Nasal, Temporal, Superior, and Inferior quadrants again to correspond to classic OCT imaging measures but also potentially into more refined octants) to sub-sample the retina (monocularly) or the visual field (binocularly), thus parceling the data into smaller subregions organized in polar coordinates to better correspond to classic OCT imaging and other clinical imaging measures. This enables ECO to detect spatially localized impairments that would otherwise be blurred out by larger healthy regions of the retina/brain and allows for direct comparison with clinical OCT results and other clinical imaging systems. ECO sectors/rings could be tailored to enable comparison with brain MRI/A (Magnetic Resonance Imaging/Angiography) or CAT (Computer Aided Tomography) commonly used in neurology clinics so that the structural damage or pathology revealed by these standard imaging techniques can be correlated to actual function loss in corresponding sub-regions of the visual field in support of both clinical and research applications.

Current subcutaneous vessel imagers use large, multiple, and often separate assemblies with complicated optics to image subcutaneous structures as two-dimensional maps on a wide monitor, or as maps extracted by a computer and focused onto the skin by a video projection. The scattering of infrared light that takes place during this process produces images that are shadowy and distorted. By contrast, Glenn's innovative approach offers a relatively compact and inexpensive alternative to the conventional setup, while also producing clearer images that can be rendered in either two or three dimensions. Glenn's device uses off-the-shelf near-infrared technology that is not affected by melanin content and can also operate in dark environments. In Glenn's novel subcutaneous imager, a camera is configured to generate a video frame. Connected to the camera is a processor that receives the signal for the video frame and adjusts the thresholds for darkness and whiteness. The result is that the vein (or other subcutaneous structure) will show very dark, while other surrounding features (which would register as gray) become closer to white due to the heightened contrast between thresholds. With no interval of complex algorithms required, the image is presented in real-time on a display, yielding immediate results. Glenn's advanced technology also allows the operator to achieve increased depth perception through the synchronization of a pair of imaging devices. Additionally, the novel use of a virtual-reality headset affords a three-dimensional view of the field, thereby improving the visualization of veins. In short, Glenn's researchers have produced an inexpensive, lightweight, high-utility device for locating and identifying subcutaneous structures in patients.